Monday, March 02, 2020 8:16:09 AM
One needs to think of the patient population. The R&D presentation had 5M Alzheimer's patients and Parkinson's was 1M. A genome regulation would be likely priced as gene therapy, at $1M. The market potential is about $6 Trillion. At 9% royalty, think $540B to Sangamo. agreement means to Sangamo. BTW Biogen shares are in an escrow, cannot be sold for one year, and then they may be sold in 50% drops until 5% is reached.
Biogen is also forbidden to buy shares on the open market, just in case they want to take over, or worse sell short own holding.
Pfizer is adding two patients to phase 2 to copy BioMarin 7 patients and have a mirror image. Judging by the moves of BioMarin, Pfizer could be filing BLA by February 2021. Between now and then, data drops to keep BioMarin at bay would be likely. At $10, including Biogen investment, the stock is worth $1.4B. Biogen did not select CRSP for it, as the method cannot make precise regulation. Vertex sold half shares of CRSP, but WS barrel fish bought up CRSP to over $4.2B. That's $33 for Sangamo share. None of the CRSP deals are like the ones for Sangamo, and Vertex seems to be moving out, not because it needs money.
Keep your shares, people,
17% shares in Biogen's hands. That is the point. Shorts are not getting those shares. Equity investment is much more attractive than selling to the markets, and shorts to cover. Sangamo is getting $350M, and secures cash runway for another two years, in worse case 2023.
https://www.sangamo.com/pipeline
$SGMO
Recent SGMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:38:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:38:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:37:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:37:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:36:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:34:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:02:42 PM
- Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results • Business Wire • 08/06/2024 08:01:00 PM
- Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases • Business Wire • 08/06/2024 12:05:00 PM
- Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast • Business Wire • 07/30/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:05:28 PM
- Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate • Business Wire • 07/24/2024 10:55:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/08/2024 08:32:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:42:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:26:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:25:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:25:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:24:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:24:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:23:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:23:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:23:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 09:18:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 09:15:56 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM